{
    "clinical_study": {
        "@rank": "139574", 
        "acronym": "EGOFIP", 
        "arm_group": [
            {
                "arm_group_label": "victoza", 
                "arm_group_type": "Active Comparator", 
                "description": "The study is a cross over study. Patients randomised to start with victoza are treated with victoza for 10 weeks. After a wash out period of 2 weeks they cross over to 10 weeks of no treatment"
            }, 
            {
                "arm_group_label": "No treatment", 
                "arm_group_type": "No Intervention"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to determine if a GLP-1 agonist improves microvascular perfusion\n      in the heart of patients with type 2 diabetes"
        }, 
        "brief_title": "Effect of Glucagon-like Peptide 1 (GLP-1) on Microvascular Myocardial Function in Patients With Type 2 Diabetes.", 
        "condition": [
            "Type 2 Diabetes", 
            "Microvascular Dysfunction"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Type 2 diabetes on monotherapy with metformin or sulfonylurea or combination  therapy\n             of metformin and sulfonylurea.\n\n          -  Age: 25-75 years\n\n          -  BMI>25 kg/m2\n\n          -  HbA1c 6,0-10 %\n\n        Exclusion Criteria:\n\n          -  Current treatment with insulin or Dipeptidyl peptidase IV inhibitor.\n\n          -  Haemoglobin < 6.5 mmol/l\n\n          -  Documented significant stenosis of the left anterior descending artery (LAD) at\n             coronary angiography or CT-angiography or regional dysfunction documented during\n             dipyridamol stress-echocardiography. If stress test at baseline shows significant\n             stenosis the patient will be excluded from the study.\n\n          -  Allergy towards victoza \u00ae (liraglutide ), Dipyridamol, Nitroglycerin or rescue\n             medicine: Theophyllin\n\n          -  Pregnancy\n\n          -  Severe asthma\n\n          -  Active cancer\n\n          -  Severe co-morbidity with limited life-expectancy\n\n          -  Estimated glomerular filtration rate (eGFR) <60 (measured at baseline)\n\n          -  Severe hepatic co-morbidity\n\n          -  Chronic alcohol abuse\n\n          -  Heart failure with a left ventricular ejection fraction </= 45%\n\n          -  Atrial fibrillation\n\n          -  Chronic or previous acute pancreatitis\n\n          -  Inflammatory bowel disease."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "25 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01931982", 
            "org_study_id": "eudraCT: 2012-005013-38", 
            "secondary_id": "2012-005013-38"
        }, 
        "intervention": {
            "arm_group_label": "victoza", 
            "intervention_name": "Victoza", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Glucagon-Like Peptide 1", 
                "Glucagon"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "diabetes, GLP-1, Victoza, CFR, microvascular dysfunction", 
        "lastchanged_date": "August 27, 2013", 
        "location": {
            "contact": {
                "email": "m.zander@dadlnet.dk", 
                "last_name": "Mette Zander, consultant", 
                "phone": "0045 5154 3686"
            }, 
            "contact_backup": {
                "email": "Eva.Irene.Bossano.Prescott@regionh.dk", 
                "last_name": "Eva Prescott, professor", 
                "phone": "0045 22572614"
            }, 
            "facility": {
                "address": {
                    "city": "Copenhagen", 
                    "country": "Denmark", 
                    "state": "Capital region", 
                    "zip": "2400"
                }, 
                "name": "Bispebjerg Hospital"
            }, 
            "investigator": {
                "last_name": "Mette Zander, Consultant", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of GLP-1 on Microvascular Myocardial Function in Patients With Type 2", 
        "other_outcome": [
            {
                "measure": "Changes in HbA1c", 
                "safety_issue": "No", 
                "time_frame": "Measurements at baseline and after 10 weeks of intervention"
            }, 
            {
                "measure": "Change in fasting C-peptide", 
                "safety_issue": "No", 
                "time_frame": "C-peptide is measured at baseline and after 10 weeks of intervention"
            }, 
            {
                "measure": "Change in fasting insulin", 
                "safety_issue": "No", 
                "time_frame": "Fasting insulin is measured at baseline and after 10 weeks of intervention"
            }, 
            {
                "measure": "Change in fasting glucose", 
                "safety_issue": "No", 
                "time_frame": "Fasting glucose is measured at baseline and after 10 weeks of intervention"
            }, 
            {
                "measure": "Change in weight", 
                "safety_issue": "No", 
                "time_frame": "Weight is measured at baseline and after 10 weeks of intervention"
            }, 
            {
                "measure": "Change in waist circumference", 
                "safety_issue": "No", 
                "time_frame": "Waist circumference is measured at baseline and after 10 weeks of intervention"
            }
        ], 
        "overall_official": {
            "affiliation": "Department of Endocrinology, Bispebjerg Hospital", 
            "last_name": "Mette Zander, consultant", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Denmark: Danish Dataprotection Agency", 
                "Denmark: Danish Health and Medicines Authority", 
                "Denmark: Ethics Committee"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "CFR can be reliably assessed non-invasively by trans-thoracic Doppler flow echocardiography of the left anterior descending artery with a success rate of over 90% even in an obese population with a relative poor acoustic window. CFR is the ratio of flow during stress to during rest.", 
            "measure": "Change in coronary flow reserve (CFR)", 
            "safety_issue": "Yes", 
            "time_frame": "CFR is measured at baseline and after 10 weeks of intervention"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01931982"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Bispebjerg Hospital", 
            "investigator_full_name": "Mette Zander", 
            "investigator_title": "MD, PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Measurement of Peripheral Arterial Tone, with the use of the commercially available machine (Endo-PAT2000\u00ae) assesses the control of digital vascular tone by the sympathetic nervous system and nitric oxide (NO).", 
            "measure": "Change in Endothelial function:", 
            "safety_issue": "Yes", 
            "time_frame": "Endothelial function is measured at baseline and after 10 weeks of intervention"
        }, 
        "source": "Bispebjerg Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bispebjerg Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}